In addition to bevacizumab, two other nonbone drugs approved by the US Food and Drug Administration (FDA), Sutent (sunitinib malate for gastrointestinal and pancreatic tumors and renal cell carcinoma), and Nexavar (sorafenib for hepatocellular carcinoma), have potential roles in increasing risk for ONJ, most likely by interfering with VEGF signaling.58 Disruption of VEGF could compromise the integrity of the vasculature in the jaw, or by causing host defense impairment. Here, VEGFA is linked to hereditary clear cell renal cell carcinoma.